Radiogenomic evaluation of tumour response to targeted agents
Radiogenomics should be an integral part of drug development, according to Dr Korn who talks to ecancer about this evolving field at TAT 2015.
Dr. Ron Korn of Imaging Endpoints to Present at Pharmatech’s Biomarker Panel
April 2014 - Ron Korn, MD, PhD, of Imaging Endpoints will be a featured presenter at Pharmatech's Biomarker Panel entitled "Development of Oncology Clinical Trials in the time of Precision, Personalized Medicine" occurring on May 15, 2014 at the Marriott… Read More
ALK Molecular Phenotype in Non-Small Cell Lung Cancer: CT Radiogenomic Characterization
Purpose: To present a radiogenomic computed tomographic (CT) characterization of anaplastic lymphoma kinase (ALK) rearranged non–small cell lung cancer (NSCLC) (ALK+). Materials and Methods: In this HIPAA-compliant institutional review board–approved retrospective study, CT studies, ALK status, and clinical-pathologic data in… Read More
Noninvasive Image Texture Analysis Differentiates K-ras Mutation from Pan-Wildtype NSCLC and Is Prognostic
Abstract Background: Non-invasive characterization of a tumor’s molecular features could enhance treatment management. Quantitative computed tomography (CT) based texture analysis (QTA) has been used to derive tumor heterogeneity information, and the appearance of the tumors has been shown to relate… Read More
AG Mednet and Imaging Endpoints Partner to Set Clinical Trial Benchmark for Image Data Quality and Compliance
Boston, MA – May 7, 2014 – AG Mednet and the board-certified, fellowship-trained radiologists at Imaging Endpoints believe strongly that every clinical trial data point counts, from pre-clinical through FDA submission. To support its guarantee of accuracy, compliance, real-time reads… Read More
